International: +1-347-960-6455
Prostatitis Therapeutics Pipeline to Witness Remarkable Growth due to Increased Number of Pipeline Candidates by Drug Developers

According to a new research report Prostatitis Therapeutics – Pipeline Analysis 2019, Clinical Trials and Results, Patents, Designations, Collaborations, and Other Developments” published by Pharma Proff, prostatitis therapeutics currently exhibits a proliferating pipeline with 12+ therapeutic candidates.

Prostatitis Therapeutics Pipeline Insights

Prostatitis refers to a group of disorders that lead to inflammatory condition causing pain in prostate gland. The disease is categorized into four forms: chronic pelvic pain syndrome (CPPS), acute bacterial prostatitis, chronic bacterial prostatitis, and asymptomatic prostatitis. CPPS, also called prostatodynia is the occurrence of prostatitis symptoms, without inflammation or bacterial infections. Acute bacterial prostatitis is described as inflammation of the prostate gland caused by bacteria such as Escherichia coli and Klebsiella. Chronic bacterial prostatitis is the recurrent infection and inflammation of the prostate and urinary tract, and asymptomatic prostatitis is an uncommon type wherein the patient experiences an inflamed prostate without any bacterial infection.

The chronic pelvic pain syndrome leads to pain in penis, lower back, scrotum, central lower abdomen, and between scrotum and anus, acute bacterial prostatitis and chronic bacterial prostatitis tend to change urinary frequency, fever, chills, burning sensation during urination, urinary blockage, nausea, and vomiting, whereas patients with asymptomatic prostatitis do not have symptoms of prostatitis.

The occurrence of prostatitis can be diagnosed by a physical examination, blood test digital rectal exam (DRE), prostate-specific antigen (PSA) blood test, and cystoscopy and urodynamic tests. Some of the commonly used treatment options include medications (antibiotics, alpha-blockers, and anti-inflammatory agents), lifestyle changes, and acupuncture.

In addition, Rapaflo (Kissei Pharmaceutical Co. Ltd.), Proscar (Merck & Co. Inc.), Avodart (GlaxoSmithKline plc), and Pamelor (Mallinckrodt LLC) are some of the drugs approved by the U.S. Food and Drug Administration (USFDA) for the treatment of prostatitis.

Insights into Pipeline Segments

According to the research findings, majority of the pipeline drug candidates are being developed for oral administration. It has been observed that the oral route of medications is convenient, available in delayed or rapid release formulation, less risk of systemic infections, and inexpensive in nature, and also provides improved patient’s compliance.

Positive Clinical Results are Expected to Drive the Prostatitis Therapeutics Pipeline

Companies that are involved in developing therapeutics for prostatitis have shown positive clinical results in the various phases of drug development. For instance, in September 2018, Santen Pharmaceutical Co. Ltd. announced positive data from the phase III trial of Opsiria for the treatment of patients with prostatitis. The results of the study concluded that the treatment with Opsiria had a favorable safety and tolerability profile. The study also recorded efficacy of Opsiria in lowering down the inflammation in eyes.

Browse Detailed Report at:

Global Market of Prostatitis Therapeutics is Expected to Increase Statistically in the next 10 years

Humira (AbbVie Inc.), Geocillin (Pfizer Inc.), Floxin (Ortho-McNeil-Janssen Pharmaceuticals Inc.), and Levaquin (Janssen Pharmaceuticals Inc.) are the approved drugs for the treatment of prostatitis and with the emergence of late- and mid-stage pipeline products in the market, the overall prostatitis therapeutics market is expected to grow significantly in the upcoming years.

Aquinox Pharmaceuticals Inc., AbbVie Inc., Pfizer Inc., Kissei Pharmaceutical Co. Ltd., Janssen Pharmaceuticals Inc., Merck & Co. Inc., Santen Pharmaceutical Co. Ltd., Aldeyra Therapeutics Inc., Ortho-McNeil-Janssen Pharmaceuticals Inc., GlaxoSmithKline plc, Mallinckrodt LLC, and Novartis AG are some of the key players involved in the development of therapeutic drugs indicated for the treatment of prostatitis.

Prostatitis Therapeutics Pipeline Analysis

  • By Phase
  • By Molecule Type
  • By Route of Administration
  • By Company

The report comprises detailed pipeline analysis of therapeutics being developed for the treatment of prostatitis. Comprehensive insights on the pipeline products have been provided, with special focus on strategic developments of key players, information on drug licensing, designations, financing, and grants, technological advancements, patents, and upcoming conferences. In addition, the report highlights the winning strategies of companies involved in the prostatitis therapeutics development. Detailed regulatory approval procedures in the U.S., Europe, and Japan are also provided in the report. Furthermore, the report contains competitive analysis and extensive information on monotherapies, combination therapies, targets and mechanisms of action, and drug origin with respect to prostatitis.